Press Releases Year None20212020201920182017 July 30, 2019 European Commission Grants Orphan Drug Designation for SpringWorks Therapeutics’ MEK Inhibitor, Mirdametinib, for the Treatment of Neurofibromatosis Type 1 PDF Version June 27, 2019 SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma PDF Version June 18, 2019 BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor PDF Version June 3, 2019 SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1 PDF Version May 20, 2019 SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors PDF Version May 6, 2019 SpringWorks Therapeutics Announces Initiation of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901 in Combination with BeiGene’s RAF Dimer Inhibitor Lifirafenib in Advanced or Refractory Solid Tumors PDF Version April 1, 2019 SpringWorks Therapeutics Completes $125 Million Series B Financing PDF Version March 4, 2019 SpringWorks Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference PDF Version December 20, 2018 SpringWorks Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference PDF Version November 7, 2018 SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid Tumors PDF Version Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Next page next › Last page last »
July 30, 2019 European Commission Grants Orphan Drug Designation for SpringWorks Therapeutics’ MEK Inhibitor, Mirdametinib, for the Treatment of Neurofibromatosis Type 1 PDF Version
June 27, 2019 SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
June 18, 2019 BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor PDF Version
June 3, 2019 SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1 PDF Version
May 20, 2019 SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors PDF Version
May 6, 2019 SpringWorks Therapeutics Announces Initiation of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901 in Combination with BeiGene’s RAF Dimer Inhibitor Lifirafenib in Advanced or Refractory Solid Tumors PDF Version
March 4, 2019 SpringWorks Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference PDF Version
December 20, 2018 SpringWorks Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference PDF Version
November 7, 2018 SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid Tumors PDF Version
